1. Home
  2. ABCL vs AVBP Comparison

ABCL vs AVBP Comparison

Compare ABCL & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • AVBP
  • Stock Information
  • Founded
  • ABCL 2012
  • AVBP 2021
  • Country
  • ABCL Canada
  • AVBP United States
  • Employees
  • ABCL N/A
  • AVBP N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • AVBP
  • Sector
  • ABCL Health Care
  • AVBP
  • Exchange
  • ABCL Nasdaq
  • AVBP NYSE
  • Market Cap
  • ABCL 772.9M
  • AVBP 705.8M
  • IPO Year
  • ABCL 2020
  • AVBP 2024
  • Fundamental
  • Price
  • ABCL $2.02
  • AVBP $21.25
  • Analyst Decision
  • ABCL Strong Buy
  • AVBP Strong Buy
  • Analyst Count
  • ABCL 4
  • AVBP 7
  • Target Price
  • ABCL $8.33
  • AVBP $39.29
  • AVG Volume (30 Days)
  • ABCL 4.1M
  • AVBP 234.7K
  • Earning Date
  • ABCL 05-08-2025
  • AVBP 05-12-2025
  • Dividend Yield
  • ABCL N/A
  • AVBP N/A
  • EPS Growth
  • ABCL N/A
  • AVBP N/A
  • EPS
  • ABCL N/A
  • AVBP N/A
  • Revenue
  • ABCL $23,114,000.00
  • AVBP N/A
  • Revenue This Year
  • ABCL N/A
  • AVBP $63.13
  • Revenue Next Year
  • ABCL $36.62
  • AVBP N/A
  • P/E Ratio
  • ABCL N/A
  • AVBP N/A
  • Revenue Growth
  • ABCL N/A
  • AVBP N/A
  • 52 Week Low
  • ABCL $1.89
  • AVBP $15.47
  • 52 Week High
  • ABCL $4.20
  • AVBP $36.37
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 40.97
  • AVBP 59.18
  • Support Level
  • ABCL $1.97
  • AVBP $19.80
  • Resistance Level
  • ABCL $2.08
  • AVBP $20.86
  • Average True Range (ATR)
  • ABCL 0.10
  • AVBP 1.18
  • MACD
  • ABCL 0.01
  • AVBP 0.12
  • Stochastic Oscillator
  • ABCL 29.63
  • AVBP 88.39

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About AVBP ARRIVENT BIOPHARMA INC

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Share on Social Networks: